Innoviva, Inc. (FRA:HVE)

Germany · Delayed Price · Currency is EUR

17.70

-0.10 (-0.56%)

Last updated: Dec 5, 2025, 8:04 AM CET

-1.67% (1Y)

Market Cap	1.33B
Revenue (ttm)	331.14M
Net Income (ttm)	108.54M
Shares Out	n/a
EPS (ttm)	1.30
PE Ratio	12.28
Forward PE	9.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	17.70
Previous Close	17.80
Day's Range	17.70 - 17.70
52-Week Range	14.20 - 19.20
Beta	n/a
RSI	51.33
Earnings Date	Feb 26, 2026

About Innoviva

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic o... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1996

Employees 127

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol HVE

Full Company Profile

Financial Performance

In 2024, Innoviva's revenue was $358.71 million, an increase of 15.54% compared to the previous year's $310.46 million. Earnings were $23.39 million, a decrease of -86.98%.

Financial numbers in USD Financial Statements

News

There is no news available yet.